Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.

Fabbro-Peray P, Zouaoui S, Darlix A, Fabbro M, Pallud J, Rigau V, Mathieu-Daude H, Bessaoud F, Bauchet F, Riondel A, Sorbets E, Charissoux M, Amelot A, Mandonnet E, Figarella-Branger D, Duffau H, Tretarre B, Taillandier L, Bauchet L.

J Neurooncol. 2018 Dec 6. doi: 10.1007/s11060-018-03065-z. [Epub ahead of print]

PMID:
30523606
2.

Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.

Skardelly M, Dangel E, Gohde J, Noell S, Behling F, Lepski G, Borchers C, Koch M, Schittenhelm J, Bisdas S, Naumann A, Paulsen F, Zips D, von Hehn U, Ritz R, Tatagiba MS, Tabatabai G.

Oncologist. 2017 May;22(5):570-575. doi: 10.1634/theoncologist.2016-0347. Epub 2017 Mar 30.

3.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
4.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG).

Lancet Oncol. 2012 Sep;13(9):916-26. Epub 2012 Aug 8.

PMID:
22877848
5.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M.

J Clin Oncol. 2010 Jun 1;28(16):2712-8. doi: 10.1200/JCO.2009.26.6650. Epub 2010 May 3.

PMID:
20439646
6.

Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.

Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, Tonn JC, Westphal M, Sabel M, Schlegel U, Wick W, Pietsch T, Reifenberger G, Loeffler M, Bendszus M, Weller M.

Neurology. 2017 Apr 11;88(15):1422-1430. doi: 10.1212/WNL.0000000000003809. Epub 2017 Mar 15.

7.

Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis.

Erpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, Büyükberber S.

Tumori. 2009 Mar-Apr;95(2):191-7.

PMID:
19579865
8.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.

N Engl J Med. 2005 Mar 10;352(10):987-96.

9.

Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.

Jeon HJ, Kong DS, Park KB, Lee JI, Park K, Kim JH, Kim ST, Lim DH, Kim WS, Nam DH.

Clin Neurol Neurosurg. 2009 Oct;111(8):679-82. doi: 10.1016/j.clineuro.2009.06.013. Epub 2009 Jul 28.

PMID:
19640635
10.

Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution.

Seiz M, Krafft U, Freyschlag CF, Weiss C, Schmieder K, Lohr F, Wenz F, Thomé C, Tuettenberg J.

J Cancer Res Clin Oncol. 2010 Nov;136(11):1691-5. doi: 10.1007/s00432-010-0827-6. Epub 2010 Feb 23.

PMID:
20177703
11.

Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.

Hsieh SY, Chan DT, Kam MK, Loong HH, Tsang WK, Poon DM, Ng SC, Poon WS.

Hong Kong Med J. 2017 Dec;23(6):594-8. doi: 10.12809/hkmj165002. Epub 2017 Aug 11.

12.

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group.

Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9.

PMID:
19269895
13.

Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.

Franceschi E, Depenni R, Paccapelo A, Ermani M, Faedi M, Sturiale C, Michiara M, Servadei F, Pavesi G, Urbini B, Pisanello A, Crisi G, Cavallo MA, Dazzi C, Biasini C, Bertolini F, Mucciarini C, Pasini G, Baruzzi A, Brandes AA; PERNO Study Group.

J Neurooncol. 2016 May;128(1):157-162. doi: 10.1007/s11060-016-2093-1. Epub 2016 Mar 4. Erratum in: J Neurooncol. 2018 Jan;136(1):221-222.

PMID:
26943851
14.

Post-operative management of primary glioblastoma multiforme in patients over 60 years of age.

Daróczi B, Szántó E, Tóth J, Barzó P, Bognár L, Bakó G, Szántó J, Mózes P, Hideghéty K.

Ideggyogy Sz. 2013 Nov 30;66(11-12):391-8.

PMID:
24555238
15.

Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004.

Bauchet L, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, Pallusseau L, Carnin C, Lainé K, Schlama A, Thiebaut A, Patru MC, Bauchet F, Lionnet M, Wager M, Faillot T, Taillandier L, Figarella-Branger D, Capelle L, Loiseau H, Frappaz D, Campello C, Kerr C, Duffau H, Reme-Saumon M, Trétarre B, Daures JP, Henin D, Labrousse F, Menei P, Honnorat J; Société Française de Neurochirurgie (SFNC); Club de Neuro-Oncologie of the Société Française de Neurochirurgie (CNO-SFNC); Société Française de Neuropathologie (SFNP); Association des Neuro-Oncologues d'Expression Française (ANOCEF).

Neuro Oncol. 2010 Jul;12(7):725-35. doi: 10.1093/neuonc/noq030. Epub 2010 Apr 2.

16.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.

Minniti G, De Sanctis V, Muni R, Filippone F, Bozzao A, Valeriani M, Osti MF, De Paula U, Lanzetta G, Tombolini V, Maurizi Enrici R.

J Neurooncol. 2008 May;88(1):97-103. doi: 10.1007/s11060-008-9538-0. Epub 2008 Feb 5.

PMID:
18250965
17.

Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.

Kim YH, Kim T, Joo JD, Han JH, Kim YJ, Kim IA, Yun CH, Kim CY.

Cancer. 2015 Sep 1;121(17):2926-32. doi: 10.1002/cncr.29439. Epub 2015 May 14.

18.

Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme.

De Sanctis V, Mazzarella G, Osti MF, Valeriani M, Alfó M, Salvati M, Banelli E, Tombolini V, Enrici RM.

Anticancer Drugs. 2006 Sep;17(8):969-75.

PMID:
16940807
19.

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.

Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS.

Clin Cancer Res. 2011 Jun 15;17(12):4119-24. doi: 10.1158/1078-0432.CCR-11-0120. Epub 2011 Apr 29.

20.

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.

Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE.

J Clin Oncol. 2009 Aug 10;27(23):3861-7. doi: 10.1200/JCO.2008.20.7944. Epub 2009 Jun 8.

Supplemental Content

Support Center